RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs,
were approved by the Food and Drug Administration in 2018 and 2019, respectively …

The discovery of the link between microRNAs (miRNAs) and a myriad of human diseases,
particularly various cancer types, has generated significant interest in exploring their …

The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …

In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are
some of the most important biopharmaceuticals that are in commercial space as future …

The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …

Simple Summary RNA-based drugs are an attractive approach for personalized treatment of
cancer and other diseases. This review focuses on two related classes of short non-coding …

miRNAs, short ribonucleic acid gene regulators, are increasingly popular drug targets.
Traditionally 'undruggable'proteins can be targeted via their miRNA gene regulators …

Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-
stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes …

Background miRNAs, a class of small endogenous RNAs, are one of the essential
biopharmaceuticals which are in commercial spans as next-generation medicine in recent …

RNA interference (RNAi) provides researchers with a versatile means to modulate target
gene expression. The major forms of RNAi molecules, genome-derived microRNAs …